Company Profile
Editas Medicine Stock Price, News & Catalysts
- Ticker:
- EDIT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.84 USD (+0.71%)
Close
Last updated: August 17, 2026
433M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, EDIT closed up 0.71% at $2.84. No new same-company headline was identified in the current news window.
Company overview
In Vivo CRISPR Medicines
Editas Medicine is developing in vivo CRISPR gene-editing therapies intended to produce durable therapeutic effects after a single administration. Following the discontinuation of its earlier reni-cel program, the company’s near-term strategy is concentrated on cardiometabolic editing.
EDIT-401
EDIT-401 is designed to upregulate LDL receptor protein in the liver and thereby lower LDL cholesterol. Preclinical studies showed large mean LDL-C reductions and also demonstrated reductions in apolipoprotein B and lipoprotein(a), supporting its development as a one-time treatment for hyperlipidemia.
Initial HeFH Development
The first clinical indication is heterozygous familial hypercholesterolemia, an inherited disorder that produces elevated LDL-C and early cardiovascular risk. Editas plans to use the initial trial to establish safety, dose response and human proof of concept before considering broader hyperlipidemia populations.
Future catalysts
- Initiation of the first-in-human EDIT-401 trial in 2026.
- Early human proof-of-concept data for EDIT-401 expected by year-end 2026.
- Completion of dose-finding enrollment and topline EDIT-401 results expected in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Editas Medicine (EDIT)?
Editas Medicine (EDIT) most recently closed at 2.84 USD, a +0.71% move versus the previous session.
What is the market cap of Editas Medicine (EDIT)?
Editas Medicine currently has a market capitalization of 433M USD on BioPharmSignal.
What does Editas Medicine do?
In Vivo CRISPR Medicines Editas Medicine is developing in vivo CRISPR gene-editing therapies intended to produce durable therapeutic effects after a single administration. Following the discontinuation of its earlier reni-cel program, the company’s near-term strategy is concentrated on cardiometabolic editing. EDIT-401 EDIT-401 is designed to upregulate LDL...
On which exchange is EDIT stock listed?
Editas Medicine (EDIT) is associated with NASDAQ, United States, Biopharma.
What is EDIT-401?
Initiation of the first-in-human EDIT-401 trial in 2026.
Which conditions is Editas Medicine targeting with EDIT-401?
Editas Medicine is associated with cardiovascular disease, metabolic disease based on its company overview and current catalyst commentary.
How does Editas Medicine describe recent progress with EDIT-401?
Initiation of the first-in-human EDIT-401 trial in 2026.
What is LDL-C?
Preclinical studies showed large mean LDL-C reductions and also demonstrated reductions in apolipoprotein B and lipoprotein(a), supporting its development as a one-time treatment for hyperlipidemia.